138 related articles for article (PubMed ID: 26607327)
21. Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?
Hodgkinson VC; ELFadl D; Agarwal V; Garimella V; Russell C; Long ED; Fox JN; McManus PL; Mahapatra TK; Kneeshaw PJ; Drew PJ; Lind MJ; Cawkwell L
J Proteomics; 2012 Feb; 75(4):1276-83. PubMed ID: 22115752
[TBL] [Abstract][Full Text] [Related]
22. Relationship between circulating tumor cells and epithelial to mesenchymal transition in early breast cancer.
Mego M; Cierna Z; Janega P; Karaba M; Minarik G; Benca J; Sedlácková T; Sieberova G; Gronesova P; Manasova D; Pindak D; Sufliarsky J; Danihel L; Reuben JM; Mardiak J
BMC Cancer; 2015 Jul; 15():533. PubMed ID: 26194471
[TBL] [Abstract][Full Text] [Related]
23. Fucoidan induces changes in the epithelial to mesenchymal transition and decreases metastasis by enhancing ubiquitin-dependent TGFβ receptor degradation in breast cancer.
Hsu HY; Lin TY; Hwang PA; Tseng LM; Chen RH; Tsao SM; Hsu J
Carcinogenesis; 2013 Apr; 34(4):874-84. PubMed ID: 23275155
[TBL] [Abstract][Full Text] [Related]
24. Nef-M1, a peptide antagonist of CXCR4, inhibits tumor angiogenesis and epithelial‑to‑mesenchymal transition in colon and breast cancers.
Katkoori VR; Basson MD; Bond VC; Manne U; Bumpers HL
Oncotarget; 2015 Sep; 6(29):27763-77. PubMed ID: 26318034
[TBL] [Abstract][Full Text] [Related]
25. WNT pathway inhibitor pyrvinium pamoate inhibits the self-renewal and metastasis of breast cancer stem cells.
Xu L; Zhang L; Hu C; Liang S; Fei X; Yan N; Zhang Y; Zhang F
Int J Oncol; 2016 Mar; 48(3):1175-86. PubMed ID: 26781188
[TBL] [Abstract][Full Text] [Related]
26. Epithelial to mesenchymal transition is associated with rapamycin resistance.
Holder AM; Akcakanat A; Adkins F; Evans K; Chen H; Wei C; Milton DR; Li Y; Do KA; Janku F; Meric-Bernstam F
Oncotarget; 2015 Aug; 6(23):19500-13. PubMed ID: 25944619
[TBL] [Abstract][Full Text] [Related]
27. Combined Effect of Anti-SSEA4 and Anti-Globo H Antibodies on Breast Cancer Cells.
Lee RH; Wang YJ; Lai TY; Hsu TL; Chuang PK; Wu HC; Wong CH
ACS Chem Biol; 2021 Aug; 16(8):1526-1537. PubMed ID: 34369155
[TBL] [Abstract][Full Text] [Related]
28. Molecular Pathways Mediating Metastases to the Brain via Epithelial-to-Mesenchymal Transition: Genes, Proteins, and Functional Analysis.
Jeevan DS; Cooper JB; Braun A; Murali R; Jhanwar-Uniyal M
Anticancer Res; 2016 Feb; 36(2):523-32. PubMed ID: 26851006
[TBL] [Abstract][Full Text] [Related]
29. SOX4 induces epithelial-mesenchymal transition and contributes to breast cancer progression.
Zhang J; Liang Q; Lei Y; Yao M; Li L; Gao X; Feng J; Zhang Y; Gao H; Liu DX; Lu J; Huang B
Cancer Res; 2012 Sep; 72(17):4597-608. PubMed ID: 22787120
[TBL] [Abstract][Full Text] [Related]
30. Stimulus-dependent differences in signalling regulate epithelial-mesenchymal plasticity and change the effects of drugs in breast cancer cell lines.
Cursons J; Leuchowius KJ; Waltham M; Tomaskovic-Crook E; Foroutan M; Bracken CP; Redfern A; Crampin EJ; Street I; Davis MJ; Thompson EW
Cell Commun Signal; 2015 May; 13():26. PubMed ID: 25975820
[TBL] [Abstract][Full Text] [Related]
31. Epithelial-mesenchymal transition and breast cancer: role, molecular mechanisms and clinical impact.
Foroni C; Broggini M; Generali D; Damia G
Cancer Treat Rev; 2012 Oct; 38(6):689-97. PubMed ID: 22118888
[TBL] [Abstract][Full Text] [Related]
32. MicroRNA Profile in Response to Doxorubicin Treatment in Breast Cancer.
Tormo E; Pineda B; Serna E; Guijarro A; Ribas G; Fores J; Chirivella E; Climent J; Lluch A; Eroles P
J Cell Biochem; 2015 Sep; 116(9):2061-73. PubMed ID: 25802200
[TBL] [Abstract][Full Text] [Related]
33. Expression of stage-specific embryonic antigen-4 (SSEA-4) defines spontaneous loss of epithelial phenotype in human solid tumor cells.
Sivasubramaniyan K; Harichandan A; Schilbach K; Mack AF; Bedke J; Stenzl A; Kanz L; Niederfellner G; Bühring HJ
Glycobiology; 2015 Aug; 25(8):902-17. PubMed ID: 25978997
[TBL] [Abstract][Full Text] [Related]
34. Bcl-xL mediates therapeutic resistance of a mesenchymal breast cancer cell subpopulation.
Keitel U; Scheel A; Thomale J; Halpape R; Kaulfuß S; Scheel C; Dobbelstein M
Oncotarget; 2014 Dec; 5(23):11778-91. PubMed ID: 25473892
[TBL] [Abstract][Full Text] [Related]
35. miR-655 suppresses epithelial-to-mesenchymal transition by targeting Prrx1 in triple-negative breast cancer.
Lv ZD; Kong B; Liu XP; Jin LY; Dong Q; Li FN; Wang HB
J Cell Mol Med; 2016 May; 20(5):864-73. PubMed ID: 26820102
[TBL] [Abstract][Full Text] [Related]
36. MiR-203 downregulation is responsible for chemoresistance in human glioblastoma by promoting epithelial-mesenchymal transition via SNAI2.
Liao H; Bai Y; Qiu S; Zheng L; Huang L; Liu T; Wang X; Liu Y; Xu N; Yan X; Guo H
Oncotarget; 2015 Apr; 6(11):8914-28. PubMed ID: 25871397
[TBL] [Abstract][Full Text] [Related]
37. BRCA1-IRIS inactivation overcomes paclitaxel resistance in triple negative breast cancers.
Blanchard Z; Paul BT; Craft B; ElShamy WM
Breast Cancer Res; 2015 Jan; 17(1):5. PubMed ID: 25583261
[TBL] [Abstract][Full Text] [Related]
38. Polyomavirus enhancer activator 3 protein promotes breast cancer metastatic progression through Snail-induced epithelial-mesenchymal transition.
Yuen HF; Chan YK; Grills C; McCrudden CM; Gunasekharan V; Shi Z; Wong AS; Lappin TR; Chan KW; Fennell DA; Khoo US; Johnston PG; El-Tanani M
J Pathol; 2011 May; 224(1):78-89. PubMed ID: 21404275
[TBL] [Abstract][Full Text] [Related]
39. Tumor xenograft modeling identifies an association between TCF4 loss and breast cancer chemoresistance.
Ruiz de Garibay G; Mateo F; Stradella A; Valdés-Mas R; Palomero L; Serra-Musach J; Puente DA; Díaz-Navarro A; Vargas-Parra G; Tornero E; Morilla I; Farré L; Martinez-Iniesta M; Herranz C; McCormack E; Vidal A; Petit A; Soler T; Lázaro C; Puente XS; Villanueva A; Pujana MA
Dis Model Mech; 2018 May; 11(5):. PubMed ID: 29666142
[TBL] [Abstract][Full Text] [Related]
40. Plasticity and intratumoural heterogeneity of cell surface antigen expression in breast cancer.
Remšík J; Fedr R; Navrátil J; Binó L; Slabáková E; Fabian P; Svoboda M; Souček K
Br J Cancer; 2018 Mar; 118(6):813-819. PubMed ID: 29462126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
